Continuous Compliance Monitoring for SaaS GxP Systems: Keeping Validation Current Through Every Vendor Release

Cloud and software-as-a-service platforms now run quality management, pharmacovigilance, regulatory information and laboratory processes across the industry. They also change on the vendor’s schedule, often several times a year. A validation package signed off at go-live says little about the system an inspector sees two years later. Continuous compliance monitoring, a disciplined way of assessing each release and keeping evidence current, is fast becoming the expectation rather than the exception.

Why the old model breaks

Traditional computerised system validation assumed that the regulated company controlled when software changed. With SaaS, the supplier controls the release cycle, and the regulated company remains responsible for demonstrating that the system stays fit for its intended use. EU GMP Annex 11 already requires supplier oversight, change control and periodic evaluation, and the draft revision consulted on in 2025 places even more weight on written agreements, ongoing supplier monitoring and routine audit-trail review. FDA’s Computer Software Assurance guidance and GAMP 5 Second Edition both point the same way: focus assurance effort on what matters to patient safety, product quality and data integrity.

What continuous monitoring looks like

  • Release triage: every vendor release note is reviewed, and each change is mapped to your requirements and intended use.
  • GxP impact rating: changes are rated for their effect on regulated functions, so that cosmetic updates and critical changes are not treated the same way.
  • Targeted regression: testing focuses on the functions affected, using scripted, unscripted or hybrid approaches in proportion to risk.
  • Control evidence: Annex 11 and Part 11 controls, such as audit trails, access management and electronic signatures, are tracked against current evidence rather than the original validation.
  • Readiness indicators: open gaps, overdue periodic reviews and untested releases are visible before an inspection, not during it.

Common gaps inspectors find

  • Supplier agreements that do not give audit rights or advance notice of changes
  • Releases accepted without any documented impact assessment
  • Periodic reviews that repeat the original validation summary instead of assessing what has changed
  • No plan for AI functionality that vendors add to existing products, which the draft Annex 22 would bring into scope where it supports critical GMP decisions

Tooling for the job

Spreadsheets and email threads struggle to keep up with frequent releases across many systems. Purpose-built tools can help. VigiRadar, one of the platforms listed on our Software Solutions page, is designed around this workflow: supplier release triage, an Annex 11 and Part 11 control matrix, Annex 22 eligibility checks for embedded AI and per-system readiness scoring. Whatever tool is used, the regulated company still owns the decisions and the evidence.

How PQRA helps

PQRA supports risk-based computerised system validation, supplier assessments for SaaS providers, periodic review programmes and inspection preparation for GMP, GDP and pharmacovigilance systems. We help you build a monitoring process that is proportionate and defensible.

Contact PQRA about continuous compliance monitoring

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *